---- CEO Nasrat Say $160 million ----
Split = $80
---- CEO Nasrat Say $160 million ----
Split = $80 Million
$40 Million To Make Product
$40 Million Profit To ELTP
So Gross to ELTP is $80 Million now add current salesthe $20 Million = $100 Million Gross.
Company is 400% Larger on Top Of Having Recently Doubled In Size.
Quote Nasrat:
“The last SunGen that was filed in May was an extended-release CNS stimulant that we co-developed with our partner SunGen. The branded and generic sales of this product are approximately $1.6 BILLION and there are currently just FOUR meanufacturers which includes the branded and its authorized generics.“
“ This is an outstanding product for us once we get an approval because we will be the fifth in this arena, and even if there were more people than that and we've got just 10% of that market, that's $160 million, a $160 million in revenues will do wonders to Elite stock. Even if we cut it in half between us and SunGen and you take out the actual cost which is another half and walk away with only $40 million, that will take our market cap from 80 million which is today to $800 million with one product only."
$40-Million Profit, PE 20, Equals $.96 Stock Price
$40 Profit Million Divided By 832 Million Shares Outstanding Equals $.048 Per Share
$.048 X PE 20
PE 20 = $.96
PE 30 = $1.44
High Growth Companies Are Rewarded With Higher PE's
Now SunGen 5 Doubles Those PE Stock Price Numbers.
Elite Pharmaceuticals Inc (ELTP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...
Continue Reading
Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...
Continue Reading
Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...
Continue Reading
Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...
Continue Reading
A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...
Continue Reading
Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...
Continue Reading
Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....
Continue Reading
Top 5 Most Recently Viewed Articles
ZoomInfo Technologies Inc. Class Action Lawsuit Overview On October 28, 2024, a significant alert was issued to shareholders of ZoomInfo Technologies Inc. (NASDAQ: ZI) concerning a class action lawsuit. Shareholders who acquired shares during the specified class period are encouraged to reach out for potential lead plaintiff appointments, as participation in recovery is...
Continue Reading
Plug Power's Earnings Expectations Plug Power (NASDAQ: PLUG) is preparing for its quarterly earnings announcement. Investors are keenly anticipating this event, eager to see if the company can meet or even exceed marketplace expectations. Insights into earnings reports often offer an overview crucial for understanding future stock performance. Expected Earnings Per Share...
Continue Reading
Introduction to the Class Action Against Semtech Corporation In a significant development, Semtech Corporation (NASDAQ: SMTC), known for its expertise in semiconductors and digital systems, is facing a class action lawsuit that highlights serious allegations regarding its communication with investors. This lawsuit has emerged due to claims that the company misrepresented...
Continue Reading
Unprecedented Revenue Growth for NextNRG NextNRG, Inc. (NASDAQ: NXXT), a leader in AI-driven energy solutions, has reported impressive results for the second quarter emphasizing its commitment to enhancing energy infrastructure. This notable performance aligns perfectly with the company’s strategic vision to revolutionize energy management and delivery through its...
Continue Reading
John Hancock Financial Opportunities Fund (NYSE: BTO) made some noise back in its quarterly report with a distribution of $0.6500 per share, but the real question for traders is what’s behind that number. Sure, the fund was touting its commitment to consistent returns, but this ain't just a charity; investors want to know if those distributions are sustainable or if...
Continue Reading